

Novel Cell-Based Cancer Therapies

**NK Bioscience - a startup from Vancouver B.C. to address
solid tumor metastases**

Presentation to BioSeed June 8, 2026

Presenter: Michael West PhD

Novel Cell-Based Cancer Therapies



Michael West, PhD

Industry Experience


Visiting Fellow NCI NIH – Discovered key variants of histone H2A (H2A.X, H2A.Z)

Visiting Associate NIADDK – Developed first AAV vector

Allelix, Integrated Protein Technologies (founder),

Micrologix, Director of Research (Public), foundation of company's R&D activities, managing preclinical and regulatory activities, presenting company program to FDA

GlycoDesign, VP- Preclinical – realigning R&D program, re-investigating company technology, advising on clinical program



Novel Cell-Based Cancer Therapies

NK BIO

Novel
Cell-Based
Cancer
Therapies

Founder, NK Bioscience (2024)


- Foundational experimental work completed in 5 months at Life Science Innovation Hub, Calgary
- NK BIO has outgrown these facilities

Novel Cell-Based Cancer Therapies


NK BIO

Novel
Cell-Based
Cancer
Therapies

- ✓ We have created NK cell lines that overcome immunosuppression from two major sources
- ✓ They kill cultured melanoma cells under conditions that completely inhibit normal, unmodified NK cells
- ✓ They thrive in the presence of immunosuppressive factors
- ✓ We have applied for patent protection for our cell lines



Normal NK Cells +kyn – Minimal Killing



Engineered NK cells + kyn – Significant killing

Novel Cell-Based Cancer Therapies

NK BIO

Novel
Cell-Based
Cancer
Therapies

- We need seed financing to:
 - Locate to new lab facilities and hire staff
 - Expand our studies to other tumor cell lines
 - Characterize NK cell lines
 - Test in organoid systems
 - Conduct animal studies using NOD/SCID mice
 - Support patenting costs
 - Conduct a First-in-Human trial

Novel Cell-Based Cancer Therapies

NK BIO Novel
Cell-Based
Cancer
Therapies

- In discussions for lab space with:
- Oslo Cancer Centre, Flanders, Babraham Cambridge and BioLabs Toronto
- In discussions with U Vic BC, Immunosyne, Oslo to create suitable organoids for testing

Novel Cell-Based Cancer Therapies

NK BIO
Novel
Cell-Based
Cancer
Therapies

- We are also in discussions with the Riddell Centre for Immunotherapy (Calgary) to test our cell lines in first-in-human physician-sponsored trials
- Success in a first-in-human trial will enhance our ability to raise a Series A investment



Novel Cell-Based Cancer Therapies

NK BIO Novel
Cell-Based
Cancer
Therapies

We expect to complete R&D for the first indication within six months and begin a campaign for a series A raise to take us into preclinical studies and a Phase 1/2A clinical trial

Following success in the clinic, we expect that collaboration or acquisition will occur

Thank you!